Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, Y.
Right arrow Articles by Kawamori, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, Y.
Right arrow Articles by Kawamori, R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 21, Issue 1 116-120, Copyright © 1998 by American Diabetes Association

ARTICLES

Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients

Y Tanaka, Y Atsumi, K Matsuoka, T Onuma, T Tohjima and R Kawamori
Department of Medicine, Metabolism, and Endocrinology, Juntendo University, Tokyo, Japan.

OBJECTIVE: To investigate the role of glycemic control and blood pressure in the development and progression of nephropathy and to suggest goals for glycemic control and blood pressure for the prevention of nephropathy in elderly Japanese NIDDM patients. RESEARCH DESIGN AND METHODS: A total of 123 age- and diabetes duration-matched elderly Japanese NIDDM patients (aged 60-75 years; 74 normoalbuminuric and 49 microalbuminuric) were retrospectively studied for 6 years. RESULTS: The group that developed microalbuminuria from normoalbuminuria (group NM: n = 24) showed a higher 6-year mean HbA1c than the group that remained normoalbuminuric (group NN: n = 50; 9.0 +/- 0.8 vs. 8.1 +/- 0.8%, P < 0.01) in spite of no significant difference in 6-year mean blood pressure (MBP). On the other hand, the group that progressed from microalbuminuria to overt proteinuria (group MP: n = 26) showed a higher 6-year MBP than the group that remained microalbuminuric (group MM: n = 23; 106 +/- 5 vs. 95 +/- 6 mmHg, P < 0.01) in spite of no significant difference in 6-year mean HbA1c. The cutoff level of HbA1c separating group NN from group NM was 8.5% (normal range < or = 6.5%), and that of MBP separating group MM from group MP was 100 mmHg. CONCLUSIONS: Glycemic control is a more potent factor than blood pressure level on the development of microalbuminuria. However, as far as the progression of microalbuminuria to overt proteinuria is concerned, hypertension is the most crucial factor in elderly NIDDM patients. Suggested goals for glycemic control and blood pressure level for the prevention of nephropathy in elderly Japanese patients are an HbA1c of < or = 8.5% (equivalent to 7.8% in the current measurement of stable HbA1c; normal range < or = 5.8%) and an MBP of < or = 100 mmHg.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
M. B. Davidson
No Need for the Needle (at First)
Diabetes Care, October 1, 2008; 31(10): 2070 - 2071.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Buell, D. Kermah, and M. B. Davidson
Utility of A1C for Diabetes Screening in the 1999 2004 NHANES Population
Diabetes Care, September 1, 2007; 30(9): 2233 - 2235.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
K. Kalantar-Zadeh, J. D. Kopple, D. L. Regidor, J. Jing, C. S. Shinaberger, J. Aronovitz, C. J. McAllister, D. Whellan, and K. Sharma
A1C and Survival in Maintenance Hemodialysis Patients
Diabetes Care, May 1, 2007; 30(5): 1049 - 1055.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. B. Davidson
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Jellinger, Lebovitz, and Davidson
Diabetes Care, April 1, 2007; 30(4): e18 - e20.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. B. Davidson
Clinical Implications of the DREAM Study
Diabetes Care, February 1, 2007; 30(2): 418 - 420.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. T. Tran, M. D. Navar, and M. B. Davidson
Comparison of the Glycemic Effects of Rosiglitazone and Pioglitazone in Triple Oral Therapy in Type 2 Diabetes.
Diabetes Care, June 1, 2006; 29(6): 1395 - 1396.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. L. Caramori, P. Fioretto, and M. Mauer
Enhancing the Predictive Value of Urinary Albumin for Diabetic Nephropathy
J. Am. Soc. Nephrol., February 1, 2006; 17(2): 339 - 352.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. B. Davidson
Early Insulin Therapy for Type 2 Diabetic Patients: More Cost Than Benefit
Diabetes Care, January 1, 2005; 28(1): 222 - 224.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
R. Roy, M. Navar, G. Palomeno, and M. B. Davidson
Real World Effectiveness of Rosiglitazone Added to Maximal (Tolerated) Doses of Metformin and a Sulfonylurea Agent: A systematic evaluation of triple oral therapy in a minority population
Diabetes Care, July 1, 2004; 27(7): 1741 - 1742.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. B. Davidson
Triple Therapy: Definitions, application, and treating to target
Diabetes Care, July 1, 2004; 27(7): 1834 - 1835.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
D. L. Schriger and B. Lorber
Lowering the Cut Point for Impaired Fasting Glucose: Where is the evidence? Where is the logic?
Diabetes Care, February 1, 2004; 27(2): 592 - 595.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. B. Davidson
The Case for "Outsourcing" Diabetes Care
Diabetes Care, May 1, 2003; 26(5): 1608 - 1612.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
H. P. Chase
Glycemic Control in Prepubertal Years
Diabetes Care, April 1, 2003; 26(4): 1304 - 1305.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
U. Krishnamurti and M. W. Steffes
Glycohemoglobin: A Primary Predictor of the Development or Reversal of Complications of Diabetes Mellitus
Clin. Chem., July 1, 2001; 47(7): 1157 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
M. B. Davidson
How Do We Diagnose Diabetes and Measure Blood Glucose Control?: View 1: (Diagnosing) A Clinical Basis for the Diagnosis of Diabetes
Diabetes Spectr, April 1, 2001; 14(2): 67 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Qual Saf Health CareHome page
A Melville, R Richardson, D Lister-Sharp, and A McIntosh
Complications of diabetes: renal disease and promotion of self-management
Qual. Saf. Health Care, December 1, 2000; 9(4): 257 - 263.
[Full Text]

Home page
 American Journal of Medical QualityHome page
M. B. Davidson, V. J. Karlan, and T. L. Hair
Effect of a Pharmacist-Managed Diabetes Care Program in a Free Medical Clinic
American Journal of Medical Quality, July 1, 2000; 15(4): 137 - 142.
[Abstract] [PDF]

Home page
 JAMAHome page
K. Rayburn, A. M. Saunders, M. B. Davidson, M. B. Davidson, D. L. Schriger, A. L. Peters, B. Lorber, and F. Vinicor
Glycosylated Hemoglobin as a Diagnostic Test for Type 2 Diabetes Mellitus
JAMA, February 2, 2000; 283(5): 605 - 607.
[Full Text] [PDF]

Home page
 JAMAHome page
M. B. Davidson, D. L. Schriger, A. L. Peters, and B. Lorber
Relationship Between Fasting Plasma Glucose and Glycosylated Hemoglobin: Potential for False-Positive Diagnoses of Type 2 Diabetes Using New Diagnostic Criteria
JAMA, April 7, 1999; 281(13): 1203 - 1210.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1998 by the American Diabetes Association.